Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03044613 · ClinicalTrials.gov registry record · Phase 1

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

A Phase 1 study of Gastric Cancer and Esophageal Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Active
Registry status
Phase 1
Development phase
32
Enrollment target
3
Study locations

NCT03044613 is a Phase 1 study of Gastric Cancer and Esophageal Cancer that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 32 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03044613, a Phase 1 study of Gastric Cancer and Esophageal Cancer, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor microenvironment that will improve survival.

Conditions Studied

Gastric Cancer Esophageal Cancer GastroEsophageal Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Nivolumab
  • DRUG Relatlimab
  • DRUG Paclitaxel
  • RADIATION Radiation

Study Locations (3)

Maryland

  • Johns Hopkins University - Baltimore

Pennsylvania

  • Alleghany Health Network - Pittsburgh

Texas

  • Baylor University/ Charles A. Sammons Cancer Center - Dallas

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-07-11
Est. Completion 2027-08
Phase Phase 1

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03044613

The ClinicalTrials.gov registry entry for NCT03044613 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT03044613 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT03044613 about?

NCT03044613 is a clinical study titled "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer". Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor micr...

What is the current status of trial NCT03044613?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-07-11. Estimated completion is 2027-08.

What conditions does trial NCT03044613 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer.

What interventions are being tested in trial NCT03044613?

The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Relatlimab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION).

Who is sponsoring clinical trial NCT03044613?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03044613 being conducted?

This trial has 3 study locations across Maryland, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Esophageal Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.